论文部分内容阅读
目的评价国产人用狂犬病无佐剂纯化疫苗(Vero细胞微载体)的安全性和免疫原性。方法对502人(A组)接种人用狂犬病无佐剂纯化疫苗(Vero细胞微载体)另100人(B组)作为对照接种巴斯德公司生产的狂犬病纯化疫苗。采用0、3、7、14和28天程序,观察每针次接种后72小时内局部和全身反应及14天、45天的免疫应答水平。结果所有接种对象均未出现严重局部和全身副反应。首剂免疫14天,A、B组抗体阳性率均达到100%,几何平均滴度为5.2IU/ml和5.6IU/ml。第45天,A组抗体几何平均滴度上升至9.5IU/mll,与B组相似(9.8IU/ml)。结论人用狂犬病无佐剂纯化疫苗(Vero细胞微载体)具有良好安全性和免疫原性。
Objective To evaluate the safety and immunogenicity of domestic rabies vaccine without adjuvant (Vero cell microcarrier). Methods A total of 502 rabbits (Group A) were vaccinated with human rabies vaccine without Vero cells (Vero cell microcarrier) and another 100 rabbits (Group B) were used as controls to inoculate Pasteur purified rabies vaccine. The 0, 3, 7, 14 and 28 days were used to observe the local and systemic reactions within 72 hours after each needle inoculation and the level of immune response on days 14 and 45. Results All the vaccinated subjects did not have serious local and systemic side effects. The first immunization 14 days, A, B group antibody positive rate reached 100%, the geometric mean titer of 5.2IU / ml and 5.6IU / ml. On day 45, the geometric mean titer of antibody in group A rose to 9.5 IU / mll, similar to group B (9.8 IU / ml). Conclusion The rabies vaccine without human adjuvant (Vero cell microcarrier) has good safety and immunogenicity.